Kratz, Jeremy David
Klein, Alyssa Barchet
Gray, Courtney Beth
Märten, Angela
Vilu, Hanna-Liisa
Knight, Jennifer Francesca
Kumichel, Alexandra
Ueno, Makoto
Funding for this research was provided by:
Boehringer Ingelheim
Article History
Accepted: 16 July 2024
First Online: 20 September 2024
Declarations
:
: This work was sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.
: Jeremy Kratz received honoraria from Boehringer Ingelheim GmbH and I-MAB Biopharma US Limited as well as research funding from Boehringer Ingelheim GmbH, I-MAB Biopharma US Limited, Genentech, Inc. and Vicernx Pharma. Makoto Ueno received honoraria from Taiho Pharmaceutical Co., Ltd., AstraZeneca, K.K, Yakult Honsha Co., Ltd., MSD K.K, Nihon Servier Co., Ltd., Ono Pharmaceutical Co., Ltd., Incyte Biosciences Japan GK, Chugai Pharmaceutical Co., Ltd., Boehringer Ingelheim GmbH, J-pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd. and Novartis Pharma K.K. as well as research funding from Taiho Pharmaceutical Co., Ltd., AstraZeneca, K.K, MSD K.K, Nihon Servier Co., Ltd., Ono Pharmaceutical Co., Ltd., Incyte Biosciences Japan GK, Chugai Pharmaceutical Co., Ltd., Boehringer Ingelheim GmbH, J-pharma Co., Ltd., Eisai Co., Ltd., Novartis Pharma K.K, Astellas Pharma Inc., J-pharma Co., Ltd., DFP (Delta Fly Pharma), Inc., Novocure GmbH and Chiome Bioscience Inc. Alyssa Klein, Courtney Gray and Angela Märten are employees of Boehringer Ingelheim. Hanna-Liisa Vilu, Jennifer Knight and Alexandra Kumichel are employees of Evidera, and received consulting fees from Boehringer Ingelheim to conduct this research and develop the manuscript.
: Not applicable.
: Not applicable.
: Not applicable.
: The majority of data described in this article was sourced from published works as cited throughout. In addition, the following databases were used and are cited where appropriate: International Agency for Research on Cancer (IARC); Globocan 2022 (version 1.1), available here: . National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER). SEER*Explorer, available here: . My Cancer Genome<sup>®</sup>. Vanderbilt-Ingram Cancer Center, available here: .
: Not applicable.
: Conceptualisation and design: ABK, CBG, AM and HLV; Data collection, analysis and interpretation: JDK, MU; HLV, JFK, and AK; Original draft preparation: HLV, JFK and AK; Interpretation and critical revision of the manuscript: JDK, MU, ABK, CBG and AM; Review and editing: JDK, MU; ABK, CBG, AM, HLV, JFK and AK.